Description
ATN-161 is a novel peptide antagonist of integrin α5β1. ATN-161 selectively binds to and blocks the receptor for integrin α5β1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. It has potential antineoplastic activity.
Antagonist activity